CorestemChemon Inc.
CorestemChemon is a KOSDAQ-listed (166480) cell-therapy company based in Seongnam. Its ALS treatment NEURONATA-R received conditional approval in South Korea in May 2026.
| Headquarters | Seongnam, South Korea |
|---|---|
| Listing | KOSDAQ:166480 |
| Lead asset / stage | NEURONATA-R Conditionally approved — South Korea |
| Latest event | CorestemChemon disclosed exercise of exchange rights on its second, third and fourth bond series. |